The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Weight loss drugs have surged in popularity, with millions turning to medications like Ozempic and Wegovy in hopes of shedding excess weight and managing diabetes. These drugs, classified as GLP-1 ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Weight loss drugs are popular—but often expensive. Luckily, there are a few ways to lower the costs, which we explore in this article.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Cancel anytime. Klarity - Weight Loss Looking for weight loss options? GLP-1 agonist medications, originally designed to manage type 2 diabetes, are now FDA-approved for weight management.

Looking for weight loss options? GLP-1 agonist medications, originally designed to manage type 2 diabetes, are now FDA-approved for weight management. Klarity connects you with healthcare ...